Dr. Marty Makary

85% of healthcare workers did not get the COVID booster last season. Yes. What does that tell you?

That's what they're saying. It's always the same couple doctors that these news outlets are citing. It's their go-to people. These are the same folks that misled us during COVID. And so – No, look, I think we've got to rebuild public trust. The way you do that is being incredibly honest. We're being very transparent with everything we're doing at the FDA.

That's what they're saying. It's always the same couple doctors that these news outlets are citing. It's their go-to people. These are the same folks that misled us during COVID. And so – No, look, I think we've got to rebuild public trust. The way you do that is being incredibly honest. We're being very transparent with everything we're doing at the FDA.

That's what they're saying. It's always the same couple doctors that these news outlets are citing. It's their go-to people. These are the same folks that misled us during COVID. And so – No, look, I think we've got to rebuild public trust. The way you do that is being incredibly honest. We're being very transparent with everything we're doing at the FDA.

Dr. Vinay Prasad and I just published in the New England Journal of Medicine last week our framework of how we see COVID vaccine regulation, basically saying we've got to get back to both gold standard science and common sense. We've got to be practical. It's been four years since we've had randomized trials in humans that showed an efficacy. It was a very different virus then. It was

Dr. Vinay Prasad and I just published in the New England Journal of Medicine last week our framework of how we see COVID vaccine regulation, basically saying we've got to get back to both gold standard science and common sense. We've got to be practical. It's been four years since we've had randomized trials in humans that showed an efficacy. It was a very different virus then. It was

Dr. Vinay Prasad and I just published in the New England Journal of Medicine last week our framework of how we see COVID vaccine regulation, basically saying we've got to get back to both gold standard science and common sense. We've got to be practical. It's been four years since we've had randomized trials in humans that showed an efficacy. It was a very different virus then. It was

a better match with the circulating virus. There was low natural immunity in the population. And we learned that some of that effect was transient. That is, your baseline risk came back to almost the baseline level after a transient period. We cannot be blind. We have to use a scientific approach. And we do that for every other drug at the FDA, right?

a better match with the circulating virus. There was low natural immunity in the population. And we learned that some of that effect was transient. That is, your baseline risk came back to almost the baseline level after a transient period. We cannot be blind. We have to use a scientific approach. And we do that for every other drug at the FDA, right?

a better match with the circulating virus. There was low natural immunity in the population. And we learned that some of that effect was transient. That is, your baseline risk came back to almost the baseline level after a transient period. We cannot be blind. We have to use a scientific approach. And we do that for every other drug at the FDA, right?

Cures for cancer, you know, and it's for certain types of cancer, that is, not all cancer. And why does it take 10 years for a drug to come to market in the United States? We've got to ask these big questions. So we're streamlining the process every place we can.

Cures for cancer, you know, and it's for certain types of cancer, that is, not all cancer. And why does it take 10 years for a drug to come to market in the United States? We've got to ask these big questions. So we're streamlining the process every place we can.

Cures for cancer, you know, and it's for certain types of cancer, that is, not all cancer. And why does it take 10 years for a drug to come to market in the United States? We've got to ask these big questions. So we're streamlining the process every place we can.

It's the great American ripoff. So what's going on here with these prices? We're getting taken advantage of. I mean, I think they're laughing at us. In other countries, they negotiate, you know, sweetheart deals that the drug companies give them in other countries. So a drug can be one-tenth the price, you know, a drug for $1,100, $1,200 in the United States. Yeah.

It's the great American ripoff. So what's going on here with these prices? We're getting taken advantage of. I mean, I think they're laughing at us. In other countries, they negotiate, you know, sweetheart deals that the drug companies give them in other countries. So a drug can be one-tenth the price, you know, a drug for $1,100, $1,200 in the United States. Yeah.

It's the great American ripoff. So what's going on here with these prices? We're getting taken advantage of. I mean, I think they're laughing at us. In other countries, they negotiate, you know, sweetheart deals that the drug companies give them in other countries. So a drug can be one-tenth the price, you know, a drug for $1,100, $1,200 in the United States. Yeah.

is $88 in London and 100-some in Germany. And so they're laughing at us. Now, Pharma's budget for research and development is about 15% to 20% of their overall revenue. Their budget for marketing is 20% to 30%. So they're spending more on these commercials where everyone's dancing and singing nonstop. I mean, I watch some of these. so-called news shows.

is $88 in London and 100-some in Germany. And so they're laughing at us. Now, Pharma's budget for research and development is about 15% to 20% of their overall revenue. Their budget for marketing is 20% to 30%. So they're spending more on these commercials where everyone's dancing and singing nonstop. I mean, I watch some of these. so-called news shows.

is $88 in London and 100-some in Germany. And so they're laughing at us. Now, Pharma's budget for research and development is about 15% to 20% of their overall revenue. Their budget for marketing is 20% to 30%. So they're spending more on these commercials where everyone's dancing and singing nonstop. I mean, I watch some of these. so-called news shows.

And it's basically a nonstop running pharma advertisement with an occasional insertion of some news. And then we got to go right back to break. And then it's more singing and dancing. Are these claims, are they creating an accurate picture of the claims of the medication?